Pfizer (NYSE:PFE) Stock Price Down 1.5% – Here’s Why

Pfizer Inc. (NYSE:PFE – Get Free Report) shares dropped 1.5% on Wednesday. The company traded as low as $28.00 and last traded at $28.0560. Approximately 37,233,295 shares traded hands during mid-day trading, a decline of 6% from the average session volume of 39,704,832 shares. The stock had previously closed at $28.47.

Top Pfizer Stories

Investors following PFE have been watching these stories:

Wall Street Analyst Weigh In

A number of equities analysts have commented on PFE shares. Sanford C. Bernstein reissued a “market perform” rating and issued a $29.00 price target on shares of Pfizer in a research note on Thursday, November 12th. FBN Securities set a $34.00 price target on shares of Pfizer in a report on Friday, November 6th. Weiss Ratings raised shares of Pfizer from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, November 9th. Freedom Broker upped their target price on shares of Pfizer from $33.00 to $34.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. Finally, DZ Bank cut Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, November 6th. Six investment analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and a consensus target price of $30.32.

Check Out Our Latest Analysis on PFE

Pfizer Trading Down 1.5%

The stock has a fifty day moving average of $28.82 and a two-hundred day moving average of $27.01. The company has a market capitalization of $159.91 billion, a PE ratio of 40.08, a PEG ratio of 1.90 and a beta of 0.31. The company has a current ratio of 1.42, a quick ratio of 1.10 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE – Get Free Report) last issued its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.13. Pfizer had a return on equity of 19.88% and a net margin of 6.34%. The business had revenue of $16.58 billion during the quarter, compared to analyst estimates of $15.85 billion. During the same quarter in the prior year, the firm earned $0.87 earnings per share. Pfizer’s revenue for the quarter was down .4% on a year-over-year basis. As a group, sell-side analysts anticipate that Pfizer Inc. will post 3.04 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.1%. Pfizer’s dividend payout ratio is 245.71%.

Hedge Funds Weigh In On Pfizer

Institutional investors and hedge funds have recently made changes to their positions in the business. Coastal Bridge Advisors LLC lifted its stake in shares of Pfizer by 92.0% in the 3rd quarter. Coastal Bridge Advisors LLC now owns 150,574 shares of the biopharmaceutical company’s stock valued at $4,294,000 after acquiring an additional 72,132 shares during the last quarter. Liontrust Investment Partners LLP purchased a new stake in Pfizer during the 3rd quarter valued at about $1,703,000. Zacks Investment Management grew its position in Pfizer by 1.1% during the 3rd quarter. Zacks Investment Management now owns 2,688,431 shares of the biopharmaceutical company’s stock worth $76,674,000 after acquiring an additional 30,043 shares during the last quarter. Integrated Wealth Concepts LLC grew its position in Pfizer by 8.1% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 495,799 shares of the biopharmaceutical company’s stock worth $14,140,000 after acquiring an additional 37,037 shares during the last quarter. Finally, EWA LLC purchased a new position in Pfizer in the 3rd quarter worth approximately $219,000. Institutional investors own 68.36% of the company’s stock.

About Pfizer

(Get Free Report)

Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Its work spans areas including oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and infectious diseases. The company’s products include the Prevnar family of vaccines and medicines such as Eliquis, which it commercializes with Bristol Myers Squibb, and Paxlovid. Pfizer also developed the Comirnaty COVID-19 vaccine with BioNTech.

Further Reading

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.